IceCure Medical announced preliminary unaudited U.S. revenue for ProSense systems and cryoprobes increased more than 30% in Q1 2026 compared to Q1 2025, driven by FDA clearance for low-risk breast cancer treatment in October 2025.
Key takeaways
Preliminary U.S. revenue for ProSense systems and cryoprobes increased more than 30% in Q1 2026 versus Q1 2025, based on unaudited estimates.
The revenue growth follows FDA clearance of ProSense for local treatment of low-risk breast cancer in women aged 70+ in October 2025.
An award-winning cost analysis study from Massachusetts General Hospital demonstrated cryoablation may reduce total treatment costs by more than 50% compared to breast-conserving surgery.
The Company expects to close new system sales in Q2 2026 from its expanding pipeline of prospective customers.
IceCure exhibited ProSense and participated in physician training at the Society of Breast Imaging 2026 Symposium in Seattle.
Full Q1 2026 operating and financial results are scheduled for release on May 14, 2026.